Personal information

Emails & domains

Verified email domains

Biography

Mark is Director of the CRUK Oxford Centre and Head of Oncology at the University of Oxford, where he founded the Early Phase Clinical Trials Unit. His clinical and research interests are in new cancer drug development and the treatment of upper GI cancers and melanoma. He has been Chief or Principal Investigator on >100 trials and closely involved in the development of new therapies including DNA repair, immune checkpoint and kinase inhibitors, ImmTACs and oncolytic viruses. Mark trained in Medicine at the Universities of Cambridge and Oxford, and in Oncology at the Christie Hospital and University of Manchester.

Activities

Collapse all

Employment (2)

University of Oxford: Oxford, Oxfordshire, GB

(Oncology)
Employment
Source: Self-asserted source
Mark Middleton

University of Oxford: Oxford, Oxfordshire, GB

(Department of Oncology)
Employment
Source: check_circle
ORCID Integration at the University of Oxford

Funding (16)

CRUK Oxford Centre

2022-04 to 2027-03 | Grant
Cancer Research UK (London, GB)
Source: Self-asserted source
Mark Middleton

Symplify Trial

2021-02 to 2024-03 | Grant
GRAIL LLC (London, GB)
Source: Self-asserted source
Mark Middleton

Permeabilisation of brain metastases for early and more effective treatment

2020-11-01 to 2024-12-31 | Grant
Medical Research Council (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.9555813
GRANT_NUMBER: MR/V005995/1
Source: Self-asserted source
Mark Middleton via DimensionsWizard

Permeabilisation of brain metastases for early detection and treatment

2016-06-30 to 2019-07-30 | Grant
Medical Research Council (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.5498525
GRANT_NUMBER: MR/N028031/1
Source: Self-asserted source
Mark Middleton via DimensionsWizard

Clinical Trial Research Fellowship

2015-06-01 to 2018-05-31 | Grant
Cancer Research UK (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.5139957
GRANT_NUMBER: A19716
Source: Self-asserted source
Mark Middleton via DimensionsWizard

Senior Research Nurse

2014-04-01 to 2019-03-31 | Grant
Cancer Research UK (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.5136579
GRANT_NUMBER: A18689
Source: Self-asserted source
Mark Middleton via DimensionsWizard

Novel targeted contrast agent for early detection of brain metastasis: from animal to patient stage 2

2013-06-12 to 2018-05-14 | Grant
Medical Research Council (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.2765004
GRANT_NUMBER: MR/K015443/1
Source: Self-asserted source
Mark Middleton via DimensionsWizard

Experimental Cancer Medicine Centre (ECMC): Oxford

2012-04-01 to 2017-03-31 | Grant
Cancer Research UK (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.5143294
GRANT_NUMBER: A15579
Source: Self-asserted source
Mark Middleton via DimensionsWizard

CRUKE/11/033: The PACMEL study: Randomised phase 2 study of paclitaxel with or without GSK1120212 in advanced wt BRAF melanoma

2012-01-01 to 2013-12-31 | Grant
Cancer Research UK (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.5141196
GRANT_NUMBER: A14189
Source: Self-asserted source
Mark Middleton via DimensionsWizard

CRUKE/11/017: RADVAN: Randomized phase 2 trial of whole brain radiotherapy with or without vandetanib in metastatic melanoma with brain metastases

2011-12-01 to 2013-11-30 | Grant
Cancer Research UK (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.5135804
GRANT_NUMBER: A12812
Source: Self-asserted source
Mark Middleton via DimensionsWizard

CRUK/10/008: ANZMTG-WBRT: Whole brain radiotherapy following local treatment on intracranial metastases of melanoma - a randomised phase III trial.

2010-05-01 to 2016-06-30 | Grant
Cancer Research UK (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.5141704
GRANT_NUMBER: A11885
Source: Self-asserted source
Mark Middleton via DimensionsWizard

CRUKE/10/026: DOC-MEK: A phase 2 trial of docetaxel with or without AZD6244 in wt BRAF melanoma

2010-05-01 to 2012-04-30 | Grant
Cancer Research UK (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.5138323
GRANT_NUMBER: A12154
Source: Self-asserted source
Mark Middleton via DimensionsWizard

PROM: Predicting Relapse of Melanoma at High Risk of Recurrence

2009-01-01 to 2014-12-31 | Grant
Cancer Research UK (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.5134752
GRANT_NUMBER: A8466
Source: Self-asserted source
Mark Middleton via DimensionsWizard

Oxford Experimental Cancer Medicine Centre (ECMC)

2007-04-01 to 2012-03-31 | Grant
Cancer Research UK (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.5143201
GRANT_NUMBER: A7323
Source: Self-asserted source
Mark Middleton via DimensionsWizard

CRUKD/03/039 A Cancer Research UK pharmacodynamic study of primary tumour 06-alkylguanine-DNA alkyltransferase depletion by oral PaTrin 2 (DDO)

2003-12-15 to 2007-08-14 | Grant
Cancer Research UK (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.5145996
GRANT_NUMBER: A5633
Source: Self-asserted source
Mark Middleton via DimensionsWizard

CRUKD/04/035 A Cancer Research UK Phase I trial combining CB1954 and EP0152R (NQ02) (DDO)

2001-03-16 to 2007-12-15 | Grant
Cancer Research UK (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.5149986
GRANT_NUMBER: A5632
Source: Self-asserted source
Mark Middleton via DimensionsWizard
How many people are using ORCID?